What are the top-selling drugs of BioMarin Pharmaceutical?

Overview of BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a global biotechnology company dedicated to transforming lives through scientific discovery and innovative genetic therapies. Founded in 1997, the company has built a reputation for addressing serious and often rare genetic disorders through a focused and targeted approach to drug discovery. Its culture of innovation is reinforced by an extensive research and development portfolio, which in recent years has driven significant financial and clinical successes. BioMarin’s strategic focus on areas with high unmet medical need allows it to be at the “front‐line” of developing therapies that often become the first available for rare diseases, thereby not only improving patient outcomes but also building a competitive market position.

Product Portfolio 
BioMarin’s product portfolio encompasses an array of transformative therapies comprising both enzyme replacement and gene therapies. The company’s marketed products include: 
- VIMIZIM (elosulfase alfa): Designed for the treatment of Mucopolysaccharidosis Type IVA (MPS IVA), a rare lysosomal storage disorder. 
- NAGLAZYME (galsulfase): Approved for the treatment of Mucopolysaccharidosis Type VI (MPS VI). 
- KUVAN (sapropterin dihydrochloride): Used in managing Phenylketonuria (PKU) by enhancing enzyme activity and lowering phenylalanine levels. 
- PALYNZIQ (pegvaliase-pqpz): Also indicated for PKU, addressing different patient populations or treatment paradigms. 
- VOXZOGO (vosoritide): A therapy for achondroplasia (dwarfism) that is gaining traction especially after label expansion to include younger children with open growth plates. 
- BRINEURA (cerliponase alfa): A treatment aimed at managing CLN2 disease, a form of Batten disease. 
- ROCTAVIAN (valoctocogene roxaparvovec): A gene therapy for severe hemophilia A, representing BioMarin’s move into transformative one‐time treatments. 
- ALDURAZYME (laronidase): Although not directly marketed by BioMarin, the company plays a significant role in its development for Mucopolysaccharidosis Type I (MPS I). 

Each of these therapies was carefully selected and developed based on well-understood biological mechanisms and significant unmet needs, reinforcing BioMarin’s pioneering role in the field of genetic disorders.

Top-Selling Drugs

Identification of Leading Products 
Over the years, BioMarin’s success has been driven by certain key products that have established themselves as top-selling drugs within its portfolio. Historically, its enzyme replacement therapies have been among the highest revenue generators: 
- VIMIZIM (elosulfase alfa): As reported in the 2021 annual data, Vimizim generated net product revenues of approximately US$623.1 million. Its broad adoption in the treatment of MPS IVA makes it one of the cornerstone therapies of BioMarin’s portfolio. 
- NAGLAZYME (galsulfase): Focused on the treatment of MPS VI, Naglazyme has recorded impressive sales with revenue figures around US$380.4 million in 2021, showcasing strong patient uptake and sustained market demand. 
- KUVAN (sapropterin dihydrochloride): Kuvan remains critical for PKU treatment, having achieved net product revenues of approximately US$285.8 million. Its sales trajectory, however, has been influenced recently by patent expirations and generic competition, affecting its long-term revenue potential. 
- PALYNZIQ (pegvaliase-pqpz): With net revenues reported at around US$237.5 million in 2021, Palynziq plays an important role in the PKU treatment landscape, adding to the company’s diversified revenue streams.

In addition to these established products, VOXZOGO (vosoritide) has emerged as a rising star within the portfolio. Initially contributing modestly with around US$5.9 million in early reports, the product’s rapid adoption—particularly after its label expansion to include children under 5 years old—has resulted in drastic sales performance improvements. For example, recent data indicate that Voxzogo sales jumped by 178% to US$470 million in the fourth quarter of 2023, making it one of the company’s fastest growing therapies. Additionally, its mechanism of increasing linear growth in pediatric patients with achondroplasia positions it as a novel therapeutic option in a market with no licensed alternatives in several regions.

Lastly, ROCTAVIAN (valoctocogene roxaparvovec), the gene therapy for severe hemophilia A, is positioned as a transformative product in BioMarin’s portfolio. Approved for eligible patients, its unique one-time dosing and potential long-term efficacy contribute to its market potential. Although the exact sales numbers for Roctavian have been evolving as the market dynamics mature, industry discussions note its role in transitioning BioMarin towards profitability and in complementing the revenue stream from traditional enzyme therapies.

Sales Performance Analysis 
A detailed examination of the sales performance reveals that the top-selling drugs are supported not only by solid revenue numbers but also by strategic market positioning: 

- VIMIZIM and NAGLAZYME: These therapies have historically driven a significant portion of BioMarin’s net product revenues. In the 2021 Annual Report, Vimizim achieved net revenues of US$623.1 million and Naglazyme US$380.4 million. Their sustained performance is attributable to a consistent patient base among rare disease populations and robust reimbursement models in key markets across North America, Europe, Latin America, and the Middle East. 
- KUVAN and PALYNZIQ: Although both are used in the treatment of metabolic disorders such as PKU, their sales dynamics differ. Kuvan’s performance has faced challenges following the loss of exclusivity in the U.S., which introduced generic competition and impacted its overall revenue. On the other hand, Palynziq has shown resilient growth, driven by both new patient initiations and the progression of existing patients to maintenance dosing, contributing to healthy revenue figures. 
- VOXZOGO’s Rapid Growth: The most dramatic performance improvement is evident with Voxzogo. Initially a modest revenue contributor, it has rapidly ascended as one of the top-selling products following the FDA approval of its supplemental New Drug Application (sNDA) to treat children of all ages with open epiphyses. Its sales momentum is underscored by accelerated adoption across the U.S. and European markets. Notably, in the fourth quarter of 2023, Voxzogo delivered approximately US$470 million in sales, with around 70% of new U.S. patient starts coming from children younger than 5 years old. Such impressive growth has redefined its standing from a niche product to a major revenue driver. 
- ROCTAVIAN’s Emerging Contribution: As a gene therapy with a once-off dosing regimen, Roctavian not only marks BioMarin’s entry into the gene therapy space but also holds promise for substantial market disruption. Although still early in its commercial journey, its upward trajectory in key markets such as the U.S. and Europe bolsters the company’s overall financial outlook.

Collectively, these drugs reflect a dynamic sales performance where traditional enzyme replacement therapies provide a steady revenue foundation, while newer products like Voxzogo and ROCTAVIAN are rapidly becoming key contributors to overall revenue growth and profit margins.

Factors Contributing to Sales Success

Market Demand 
The robust sales performance of BioMarin’s top-selling drugs can be attributed to several factors related to market demand:

- Unmet Medical Need: Many of BioMarin’s therapies address rare and ultra-rare genetic disorders where there was no previously approved treatment. For instance, achondroplasia and various mucopolysaccharidoses historically lacked effective therapies, resulting in strong demand once BioMarin’s treatments such as Voxzogo, Vimizim, and Naglazyme became available. 
- Patient-Centric Outcomes: Products like Voxzogo directly target improvement in linear growth and overall quality of life for pediatric patients with achondroplasia. The tangible clinical benefits have driven high levels of adoption among families and healthcare providers alike. The broadening of its indication to include younger children has further expanded the eligible patient base, thereby fueling market demand. 
- Strategic Geographic Expansion: BioMarin’s outreach to diverse markets—from North America to Europe, Latin America, and the Middle East—ensures a broad revenue base. Specific initiatives, such as expanding reimbursement agreements and navigating regulatory approvals in various regions, have helped secure a market presence for drugs like Vimizim and Naglazyme, which have enjoyed consistent usage despite regional differences in healthcare reimbursement policies. 
- Evolving Treatment Paradigms: The growing acceptance of novel therapeutic modalities, including gene therapy, plays an important role in driving market demand. Roctavian, with its innovative one-time dosing, appeals to a market perceptive of cost-effectiveness and long-term benefits, thereby complementing the traditional enzyme replacement therapies in BioMarin’s portfolio.

Competitive Advantages 
Several strategic and operational factors have contributed to the sales success of BioMarin’s top drugs:

- Innovative Research and Development Capabilities: BioMarin’s ability to harness cutting-edge genetic and molecular research has led to the development of therapies with high efficacy and safety profiles. Its focus on addressing the root causes of genetic disorders differentiates its products from competing therapies on the market. 
- First-to-Market and Exclusivity: Many of the company’s therapies were among the very first approved treatments for rare genetic disorders. For example, Vimizim and Naglazyme quickly established market dominance after approval, due in part to strong intellectual property protection and first-mover advantages. 
- Strong Clinical Evidence: The robust clinical data supporting the efficacy of these drugs have bolstered physician confidence and driven patient uptake. Voxzogo’s impressive performance data—such as significant improvements in annualized growth velocity—have not only achieved regulatory milestones but also catalyzed its rapid adoption in clinical practice. 
- Regulatory Success and Label Expansion: The successful collaboration with global health authorities such as the FDA and European Medicines Agency (EMA) has been pivotal. The strategic label expansion of Voxzogo to include children under 5 demonstrates BioMarin’s commitment to optimizing its market reach and further ingraining its products as standard-of-care options. 
- Operational Expertise and Market Strategy: BioMarin’s integrated approach to R&D and commercial operations has resulted in efficient commercialization. This operational excellence is evident from consistent revenue generation across multiple product lines, underscoring the company’s ability to manage production, pricing, and distribution in competitive global markets.

Future Outlook

Pipeline Products 
Looking forward, BioMarin’s future outlook remains promising, driven by a deep pipeline of both innovative and next-generation therapies:

- Expanding Indications for Existing Drugs: The recent approval and label expansion of Voxzogo to treat children of all ages with achondroplasia reflect a broader strategy to maximize the clinical utility of its established therapies. Moreover, pivotal trials are underway to assess the potential of Voxzogo in conditions such as hypochondroplasia, idiopathic short stature, and multiple genetic dwarfism conditions, which could further boost its market potential in the medium to long term. 
- Upcoming Advances in Gene Therapies: With ROCTAVIAN representing a breakthrough in hemophilia A treatment, ongoing clinical trials and subsequent regulatory submissions are expected to further propel its market uptake. The gene therapy space is rapidly evolving, and BioMarin’s commitment to this modality positions it for substantial future growth as these therapies gain broader acceptance. 
- Diversified Portfolio for Future Treatments: Beyond the current portfolio, BioMarin is pursuing additional product candidates in areas where significant unmet needs exist. As part of its strategic R&D prioritization, the company continues to invest in a diverse pipeline that spans commercial, clinical, and pre-clinical stages. This strategic focus not only mitigates market risk but also sets the stage for new revenue streams as these pipeline products achieve regulatory milestones.

Market Trends and Projections 
Several broader market trends and projections support BioMarin’s optimistic future outlook:

- Rising Revenue Projections: Recent financial reports suggest an upward revision of future revenue guidance, with estimates projecting BioMarin to achieve around US$3 billion in revenue in 2024. Such projections are driven by multiple factors, including the accelerated adoption of Voxzogo and the promising outlook for ROCTAVIAN, alongside strong performance from established products like Vimizim and Naglazyme. 
- Increased Market Penetration Across Global Regions: As regulatory approvals expand and reimbursement agreements are finalized in emerging markets such as Japan and regions across Europe, BioMarin’s market penetration is expected to ramp up. The addition of previously untapped markets will likely facilitate double-digit revenue growth and enhanced patient access to these transformative therapies. 
- Shift Towards Innovative Therapies: The trend in biopharmaceutical innovation is increasingly leaning toward one-time gene therapies and targeted biologics. BioMarin’s early and robust investment in these areas means that its portfolio is well-positioned to leverage emerging treatment paradigms. The shift towards such novel modalities is expected to enhance both clinical outcomes and cost-effectiveness, driving long-term adoption. 
- Policy and Reimbursement Environment: The evolving healthcare reimbursement landscape, particularly in rare diseases, is supportive of high-cost, high-value therapies. As public and private payers recognize the long-term benefits of these treatments, increased reimbursement and more favorable pricing policies are anticipated, further bolstering the commercial prospects of BioMarin’s top-selling drugs.

Conclusion 
In summary, BioMarin Pharmaceutical’s top-selling drugs are defined by a blend of historical strengths and emerging successes. The company’s foundational therapies—VIMIZIM, NAGLAZYME, KUVAN, and PALYNZIQ—have long driven substantial revenue through steady patient uptake and robust clinical efficacy. However, recent market dynamics have dramatically shifted the spotlight towards VOXZOGO, which, following an expanded indication and outstanding quarterly growth, now stands out as a major revenue driver. Additionally, the innovative gene therapy ROCTAVIAN holds considerable promise as it begins to capture market share in the treatment of severe hemophilia A.

Several factors underpin this sales success: strong market demand arising from substantial unmet needs in rare genetic disorders, the company’s competitive advantages through innovative research, first-to-market benefits, and successful regulatory strategies. Looking forward, BioMarin’s forward-looking strategy is anchored in an expanding pipeline that includes further indications for VOXZOGO and additional gene therapies, supported by favorable market trends and rebounding financial projections.

Overall, BioMarin’s strategic decisions, coupled with its strong operational execution and innovative culture, have positioned its top-selling drugs as leaders in their respective markets. This multi-faceted approach not only cements the company’s current market leadership but also provides significant momentum for sustained growth and future success as the industry continues to evolve.

Curious to see how Eureka LS fits into your workflow? From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.